22157.jpg
Type 2 Diabetes Pipeline Landscape Research 2024: Comprehensive Insights About 75+ Companies and 80+ Drugs
November 21, 2024 04:04 ET | Research and Markets
Dublin, Nov. 21, 2024 (GLOBE NEWSWIRE) -- The "Type 2 Diabetes - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering.This report provides comprehensive...
Critical Gaps in FSG
Critical Gaps in FSGS Treatment Highlight Need for New Therapies, with Pipeline Assets from Travere, Vertex, and Dimerix Poised to Address Unmet Needs
November 01, 2024 09:17 ET | Spherix Global Insights
EXTON, PA, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Focal segmental glomerulosclerosis (FSGS), one of the most common glomerular diseases seen by nephrologists, ranks among the top three rare kidney...
Diabetes Drugs Market
Diabetes Drugs Global Strategic Business Report 2024: Market to Surpass $205 Billion by 2030 - Development of GLP-1 Receptor Agonists Expands Treatment Options
September 27, 2024 09:19 ET | Research and Markets
Dublin, Sept. 27, 2024 (GLOBE NEWSWIRE) -- The "Diabetes Drugs - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for Diabetes Drugs...
EU Nephrologists For
EU Nephrologists Foresee Travere/CSL Vifor’s FILSPARITM (sparsentan) Transforming IgA Nephropathy Treatment as the First Non-Immunosuppressive Therapy
April 30, 2024 14:40 ET | Spherix Global Insights
EXTON, PA, April 30, 2024 (GLOBE NEWSWIRE) -- Over the past several years, glomerular diseases have garnered significant attention from the nephrology industry, largely driven by the persistent...
Use of SGLT2 Inhibit
Use of SGLT2 Inhibitors Continues to Expand for the Treatment of Chronic Kidney Disease, with Eli Lilly/Boehringer Ingelheim’s Jardiance Making Significant Strides Following Label Expansion
January 03, 2024 16:13 ET | Spherix Global Insights
EXTON, PA, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Since 2019, audited records of chronic kidney disease (CKD) non-dialysis patients has revealed an ongoing, annual uptick in the proportion of...
Research Nester  Logo
Global SGLT2 Inhibitors Treatment Market to Grow at a Notable CAGR During 2022-2031; Improved Healthcare System, and Growing Prevalence of Chronic Diseases Worldwide to Drive the Market Growth
July 20, 2022 08:45 ET | Research Nester
New York, July 20, 2022 (GLOBE NEWSWIRE) -- In 2019, diabetes was the ninth leading cause of death with an estimated 1.5 million deaths directly caused by diabetes. Furthermore, about 422 million...
DIABETES-DRUGS-MARKET
Diabetes Drugs Market to Reach US$ 78,261.7 Mn by 2026, Deriving Growth from Increasing Drug Approvals, says Fortune Business Insights
June 26, 2019 07:56 ET | Fortune Business Insights
Pune, June 26, 2019 (GLOBE NEWSWIRE) -- The global Diabetes Drugs Market derives growth from advancements in drug delivery systems. According to a report published by Fortune Business Insights,...
SGLT2 Inhibitors a Promising New Therapy for Type II Diabetes: New Cutting Edge Information Report Analyzes Diabetes Market Forecast Through 2013
December 12, 2008 08:12 ET | Cutting Edge Information
RESEARCH TRIANGLE PARK, NC--(Marketwire - December 12, 2008) - A new drug class is poised to make a splash in the diabetes market, according to a new report, "Diabetes Market Forecast to...